Bailong Chuangyuan(SH:605016) HTSC·2026-02-09 07:39Investment Rating - The investment rating for the company is "Buy" with a target price of RMB 31.36, reflecting a valuation premium due to the recent approval of the D-allohexose enzyme preparation [6][4]. Core Insights - The approval of the D-allohexose enzyme preparation as a food additive accelerates the domestic market for allohexose, positioning the company as a leader with significant advantages in capacity and technology [1][2]. - The company is expected to benefit from the growing health trend, with its prebiotic and dietary fiber businesses gaining traction both domestically and internationally [1][3]. - The company has a tight production capacity currently, but new production lines for functional sugars are expected to drive revenue growth in 2026 [1][3]. Summary by Sections Company Overview - The company is a global leader in allohexose production, holding the largest market share in China and the second-largest globally, with a current capacity of 15,000 tons [2]. Market Dynamics - Supply-side dynamics indicate that while many companies plan to expand production, high investment costs and immature processes may lead to rational supply growth [2]. - Demand is being driven by leading domestic companies entering the market with innovative products, such as Mengniu Dairy's introduction of D-allohexose in its new formulations [2]. Financial Projections - Revenue is projected to grow significantly, with estimates of RMB 1,737 million in 2026, reflecting a 25.99% increase from the previous year [11]. - The company's net profit is expected to reach RMB 470.81 million in 2026, with an EPS forecast of RMB 1.12 [11]. - The company maintains a high profitability level, with an expected ROE of 20.15% in 2026 [11]. Valuation - The company is assigned a PE ratio of 28x for 2026, reflecting its growth potential and market position, with a target price set at RMB 31.36 [4][6].